Results 21 to 30 of about 65,592 (243)

The price of tumor control [PDF]

, 2013
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
Bergmann, Tanja, Berking, Carola, Bockmeyer, Clemens L., Dummer, Reinhard, Eigentler, Thomas, Fluck, Michael, Garbe, Claus, Goldinger, Simone M., Grabbe, Stephan, Gutzmer, Ralf, Göppner, Daniela, Hauschild, Axel, Hein, Rüdiger, Heinzerling, Lucie M., Hundorfean, Gheorghe, Justich, Armin, Kaehler, Katharina C., Keller, Ullrich, Klein, Christina, Loquai, Carmen, Mateus, Christine, Mohr, Peter, Moos, Roger von, Paetzold, Sylvie, Robert, Caroline, Satzger, Imke, Schadendorf, Dirk, Schlaeppi, Marc, Schuler, Gerold, Schuler-Thurner, Beatrice, Trefzer, Uwe, Ulrich, Jens, Vaubel, Julia, Voskens, Caroline J., Weder, Patrik, Wilhelm, Tabea   +35 more
core   +1 more source

Treatment of Ipilimumab Induced Graves’ Disease in a Patient with Metastatic Melanoma

Case Reports in Endocrinology, 2016
Objective. Thyroid disease has been reported among the endocrinopathies that can occur after treatment with ipilimumab. Graves’ disease, however, has been rarely reported with this medication.
Umal Azmat, David Liebner, Amy Joehlin-Price, Amit Agrawal, Fadi Nabhan   +4 more
doaj   +1 more source

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

Journal for ImmunoTherapy of Cancer, 2022
Background Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1 ...
Bart Neyns, Lisa Zimmer, Caroline Robert, Celeste Lebbe, Olivier Michielin, Omid Hamid, Anne Zaremba, Oliver Klein, Ruth Plummer, Joanna Mangana, Paolo A Ascierto, Katharina C Kähler, Georgina V Long, Ryan Sullivan, Grant A McArthur, Michael Weichenthal, Egle Ramelyte, Meghan J Mooradian, Douglas B Johnson, Alexander Shoushtari, Christian U Blank, Judith M Versluis, Prachi Bhave, Claudia Trojanello, Lu Si, Inderjit Mehmi, Tasnia Ahmed, Alexander M Menzies, Adnan Khattak, Severine Roy, Matteo S Carlino, Paul C Lorigan, Clara Allayous, Rachel Roberts-Thomson, Florentia Dimitriou, Kathleen Batty, Thierry Lesimple, Serigne N Lo, Alexandre Wicky, Richard Heywood, Lena Tran, Anna Stansfeld, Julia K Schwarze, Andrea Maurichi, Hui-Ling Yeoh, Mario Santinami, Andrew M Haydon   +46 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Real world treatment sequences and outcomes for metastatic renal cell carcinoma.

PLoS ONE, 2023
ObjectivesThe treatment landscape for metastatic renal cell carcinoma changed a lot in the last few years. This study aimed to assess the treatment sequences and outcomes for metastatic renal cell carcinoma in a real-world setting.Materials and methodsWe
Gu-Shun Lai, Jian-Ri Li, Shian-Shiang Wang, Chuan-Shu Chen, Chun-Kuang Yang, Chia-Yen Lin, Sheng-Chun Hung, Kun-Yuan Chiu, Shun-Fa Yang   +8 more
doaj   +1 more source

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]

, 2018
Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John, Hertel, Nadine, Johnson, Helen, Lee, Dawn, Meng, Yang, Morais, Edith, Philips, Zoe, Roskell, Neil, Walker, Andrew   +8 more
core   +1 more source

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources

Acute visual loss after ipilimumab treatment for metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2016
Background Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs).Case ...
Melissa A. Wilson, Kelly Guld, Steven Galetta, Ryan D. Walsh, Julia Kharlip, Madhura Tamhankar, Suzanne McGettigan, Lynn M. Schuchter, Leslie A. Fecher   +8 more
doaj   +1 more source

Immunological backbone of uveal melanoma: is there a rationale for immunotherapy? [PDF]

, 2019
No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors.
Alessandra Cassano, Apte, Bill, Blom, Brigida Anna Maiorano, De Vries, Durie, Emilio Bria, Ericsson, Ernesto Rossi, Giampaolo Tortora, Gianluigi Petrone, Giovanni Schinzari, Guido Rindi, Ilaria Grazia Zizzari, Lagouros, Makitie, Maria Antonietta Blasi, Maria Grazia Sammarco, Marianna Nuti, Monica Maria Pagliara, Shaw, Sohn, Vincenzo Fiorentino, Whelchel   +24 more
core   +1 more source

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources